Methylation of DNA cytosine bases is an essential and well-studied epigenetic modification that may regulate and coordinate gene expression. Methylated gene promoter or enhancer regions are thought to block accessibility to transcriptional activators and prevent gene transcription. Numerous physiological and disease states have been associated with alterations in DNA methylation, with patterns shown to change over time in distinct cell types. 1 The majority of this plasticity is explained by DNA variants, likely to be working through a downstream effect of sequence variation on transcription factor activity. 2, 3 However, more controversially, environmental exposures, including events such as famine, may affect DNA methylation patterns, 4, 5 which in addition, can be propagated to daughter cells during cell division 6 and influence the transcription of associated genes through diverse and as yet poorly understood mechanisms. 3 The potential link between environment, changes in DNA methylation and resultant variation in gene expression that may translate into particular cellular phenotypes, has made this topic attractive to many researchers in biomedicine.
Study of DNA methylation in disease may be able to define regions of DNA that are differentially methylated between cases and controls. Knowledge of these differences could aid understanding of the pathogenesis of the disease under study or allow characterization of novel biomarkers. Importantly, DNA methylation may go some way to explain the significant non-genetic contributions to autoimmune diseases, which have proven to be elusive to date. So far, use of diverse high throughput technologies has provided mechanistic information on how abnormal methylation patterns correlate with disordered gene expression. 7 Furthermore, biomarkers based on the methylation status of small sets of genes have been validated as predictors of different outcomes in some cancers. 8 In this issue of the Journal of the American Society of Nephrology, Jones et al. 9 present a study of DNA methylation in patients with Anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) using whole blood analysis. AAV is a relapsing and remitting autoimmune disease, generally characterised by circulating ANCA, reactive to proteinase 3 (PR3) or myeloperoxidase (MPO) and thought to be triggered by certain environmental exposures, such as silica dust, infections, or drug exposure. Different disease phenotypes are recognised and more recently different genetic susceptibility loci have been identified according to ANCA serotype, with polymorphisms in HLA, PRTN3 and SERPINA1, encoding MHC molecules, PR3 and its natural inhibitor alpha-1-antitrypsin respectively, being associated with PR3-ANCA disease. 10 In their study, Jones et al, firstly examined methylation and gene expression in AAV patients and healthy controls. Secondly, they investigated whether DNA methylation patterns can be used to predict disease relapse.
In the first part, Jones et al. selected two regions of the genes, MPO and PRTN3, which encode the autoantigens MPO and PR3 respectively, and interrogated the DNA methylation status of these two regions. They found that in both genes DNA methylation was reduced in active disease compared to healthy controls, and rebounded in disease remission. They then examined expression of MPO and PRTN3 and found a negative correlation between DNA methylation and gene expression, with higher methylation levels of the assayed gene sites being associated with less expression of associated genes.
They then narrowed their study to paired samples from a subset of patients assessed longitudinally, during active disease and remission. This investigation showed that, although statistically DNA methylation was more likely to increase at the MPO and PRTN3 loci upon remission, patients could be stratified into groups who increased or decreased methylation at these loci.
Integrating expression and methylation data suggested that patients showing gene specific DNA methylation increases during remission showed a correlation with reduced expression of the associated autoantigen gene. 11 In their study, the authors could not exclude an impact of differential cell composition in the samples, as values for total white cell and neutrophil counts were missing in a significant proportion of the samples. Future studies could address this by using purified samples of a single cell subtype, or utilizing the emerging technique of single cell methylation analysis. 12 However, a further challenge is then that an overall 10-20% methylation difference may be illustrative of a mosaic subset of cells with distinct methylation states. 11 Another important consideration for the design of future experiments is DNA sequence variation. The clear importance of genetic influence on DNA methylation patterns has recently been demonstrated, and the complex and context specific interaction of sequence, methylation, transcription factor activity and gene expression remains an area of intense study. 13 An important aspect to consider is the need for a validation cohort to ensure that the findings from the studied cohort can be generalised to other AAV populations. Clearly, the study patients were carefully selected, and although enriched for previous relapse, there appeared to be no episodes of relapse in patients in the longitudinal arm between the active and remission study time points, and unusually the ANCA serotype had no impact on frequency of disease relapse. These issues and questions can be tackled by performing future prospective studies.
Overall, the work of Jones et al. represents a first and significant step linking epigenetic modifications and disease phenotype in AAV. There are other epigenetic mechanisms to be considered including the role of non-coding RNAs and histone modifications which could be addressed together in the future. There has been a recent explosion of epigenetic studies guided by large consortia and using sophisticated whole genome analyses 15 . Much of this work has looked specifically at immune phenotypes and leukocyte subtypes, which are key players in mediating autoimmune disease in response to environmental cues. Therefore, the study by Jones should represent a springboard from which the nephrology and vasculitis communities embrace these novel approaches and further investigate the role of epigenetic modifications in immune mediated kidney diseases.
